Receptor News and Research

RSS

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

Exercise remains essential alongside GLP-1 obesity treatments

As GLP-1 receptor agonists reshape obesity treatment, a new medical perspective published in the Journal of the American Medical Association, or JAMA, underscores a persistent gap in care: integrating exercise into weight management in ways patients can sustain.

5 May 2026

Phase 2 human clinical trial paves way for effective hookworm vaccine

A phase 2 human clinical trial of an antigen for a parasitic infection caused by hookworms has been shown to be effective in limiting the intensity of infection, paving the way for the development of a vaccine.

5 May 2026

Consumption of eggs can decrease risk of Alzheimer's

Consumption of eggs is associated with a lower risk of being diagnosed with Alzheimer's Disease for those 65 years and older, according to researchers at Loma Linda University Health.

5 May 2026

GLP-1 drugs combined with surgery yield superior weight loss results

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

ASPIRE trial explores survival benefits of adding chemotherapy to standard prostate cancer treatment

The Alliance for Clinical Trials in Oncology is now enrolling patients in the ASPIRE trial (A032302)-a large-scale, phase III clinical study investigating whether adding chemotherapy to current standard treatments extends survival for men with advanced prostate cancer.

4 May 2026

Study highlights stigma surrounding popular GLP-1 weight loss drugs

Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss.

4 May 2026

Protective brain pathway may slow Parkinson’s progression in females

Scientists have identified a protective brain pathway that may help slow the progression of Parkinson's disease by strengthening the brain's own dopamine‑producing neurons, but the positive effect was only observed in females.

4 May 2026

NIH awards $3.9 million grant to develop a non-opioid pain treatment

The National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH), has awarded a $3.9 million grant to a multi-institutional team led by scientists at Sanford Burnham Prebys Medical Discovery Institute to develop a non-opioid pain therapeutic and advance it into a Phase 1 clinical trial.

4 May 2026

Finding new ways to mimic ketamine’s antidepressant effects

Weill Cornell Medicine investigators have "reverse engineered" ketamine's antidepressant effects to identify potential new strategies for treating depression.

4 May 2026

Scientists find that human embryos are vulnerable to COVID

A University of California, Riverside study reports that cells in the earliest stages of human development could be susceptible to infection by SARS-CoV-2, which causes COVID-19, offering new insight into how the virus interacts with developing human tissues and why that may matter for pregnancy research.

4 May 2026

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.

30 Apr 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026

Liquid biopsy predicts immune response in high-risk breast cancer patients

Immunotherapy has become a standard of care in treating high-risk, early-stage breast cancers, yet it has had limited success in shrinking tumors.

30 Apr 2026

Antibiotic minocycline shows potential for treating panic disorder symptoms

A study supported by FAPESP shows that small doses of the antibiotic minocycline may help treat panic disorder.

30 Apr 2026

From killers to strategists: CAR T cells enter their multifunctional era

A review of 1,801 registered CAR T clinical trials shows that multifunctional designs now account for 533 trials and 33% of new CAR T products submitted for clinical testing in 2025. The field is shifting toward multitargeted, safety-controlled, cytokine-secreting, and checkpoint-modulating CAR T cells, but manufacturing, regulation, and limited clinical outcome data remain key barriers.

30 Apr 2026

Single-cell sequencing reveals why some CAR-T therapies succeed while others fail

Single-cell RNA sequencing is giving researchers a clearer view of why some CAR-T cells persist, expand, kill tumors effectively, or become exhausted. The review synthesizes 44 clinical scRNA-seq studies involving 500 patients and highlights how exhaustion, memory, cytotoxicity, clonal diversity, and metabolism may shape CAR-T responses.

30 Apr 2026

Metabolic rewiring could help CAR-T cells fight solid tumors

This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells inside solid tumors. It highlights metabolic reprogramming as a promising strategy to improve CAR-T cell persistence, adaptability, and anti-tumor function.

29 Apr 2026